What is a CRDMO?
A CRDMO (Contract Research, Development, and Manufacturing Organization) is a single outsourcing partner that combines the research and clinical-support work of a CRO with the formulation, scale-up, and manufacturing work of a CDMO. Rather than hiring separate vendors for each stage, sponsors have one organization that manages a molecule from early research through commercial-scale production.
Why CDMO?
Anyone who has helped move a new drug through early testing will tell you the same thing: the step they worry about most is "technology transfer." This is the unglamorous, paperwork-heavy stage where a drug shifts from being made in the lab to being made in a factory, and it is where many projects lose months they never recover.
For a long time, that hand-off was just the cost of doing business. A biotech would hire a CRO (Contract Research Organisation) to run its clinical trials, then separately contract a CDMO (Contract Development and Manufacturing Organisation) to work out how to actually produce the drug at scale. Two vendors, two contracts, two internal cultures, and one fragile seam where critical information could get lost.
That arrangement is being replaced. A CRDMO (Contract Research, Development, and Manufacturing Organisation) folds both jobs into a single organisation. It sounds like a small structural change, but it reshapes timelines, budgets, and how confidently investors back a program.
Where the Traditional Split Model Breaks Down
The friction here isn't really anyone's fault. It's built into the structure. Moving a candidate from a CRO's clinical testing lab to a CDMO's manufacturing floor is what the industry calls technology transfer, and in a split model, that transfer trips over the same problems again and again:
• Communication gaps: Two separate companies, running two sets of software, quality systems, and documentation standards that rarely speak to each other cleanly.
• Data loss: The small, hard-won details about how a molecule actually behaves in the lab don't always survive the move to a new team.
• Timeline drag: sourcing, vetting, and contracting a manufacturing partner from scratch can tack months onto a program that was already running tight.
None of this is catastrophic on its own. But for a lean biotech operating on a fixed runway, these delays don't just eat into budget; they put investor milestones and clinical timelines at risk.
What an Integrated CRO-CDMO Model Actually Changes
A CRDMO doesn't eliminate technology transfer so much as make it internal. It unifies the process-driven world of clinical research with the product-driven world of factory-scale manufacturing, so the hand-off happens between departments instead of between companies.
Once one organisation owns both sides, a few things happen almost immediately.
Tech transfer stops being a hand-off
Because the scientists running clinical trials and the engineers designing the manufacturing line report into the same company, information moves without a contract or an email chain standing in the way. The manufacturing team often knows what the research side has learned months before a traditional CDMO would even be looped in, which cuts down on scale-up surprises later.
Timelines compress instead of stacking
In the traditional model, manufacturing scale-up usually waits for clinical data to be finalised. An integrated CRO CDMO can safely overlap those phases, optimising the commercial formulation while trials are still running, shaving real months off time-to-market rather than just tidying up the paperwork around the edges.
Governance gets a lot simpler
Instead of juggling multiple master service agreements, sitting through duplicate quarterly business reviews, and reconciling two vendors' conflicting timelines, sponsors deal with a single point of contact. One project manager tracks the molecule's entire journey, from first assay to first commercial batch.
The financials work out better too
Consolidating spend with one partner tends to open the door to volume-based pricing, and it meaningfully cuts the administrative overhead of auditing and managing several global vendors at once. For a lot of companies, choosing a CRDMO is really an exercise in pharmaceutical supply chain optimisation, with fewer places for cost to hide.
Technical Deep Dive: It Depends on the Molecule
How much value an integrated model adds depends heavily on what's being developed.
• Small molecules: Integrated workflows let analytical chemists hand crystallisation and polymorphism data straight to the scale-up team, so commercial tablet pressing or capsule filling can be optimised without waiting on a new vendor to get up to speed.
• Biologics and advanced therapies: for mAbs, mRNA, and cell therapies, the process really is the product. Any credible biotech scale-up strategy for these modalities has to keep cell-line development, upstream and downstream purification, and commercial fill-finish inside one facility; fragile living systems don't tend to survive a rocky tech transfer.
The Investor's View: Why De-Risking Matters More Than Ever
• De-risking milestones: Investors increasingly favour startups that lean on integrated partners, since it cuts vendor-default risk and keeps data from fragmenting right before a Series B or C raise.
• Capital efficiency: Wrapping clinical milestones and early-stage scaling into a single Master Services Agreement preserves runway and keeps overall CapEx lower than running parallel contracts with a CRO and a CDMO.
Zoom out far enough, and most of this comes down to drug development outsourcing decisions that used to be made piecemeal now getting made once, with one partner accountable for the outcome.
This isn't theoretical. India's CRDMO sector alone is projected to grow from roughly $3–3.5 billion today to $22–25 billion by 2035, nearly a sevenfold increase, according to a 2025 BCG-IPSO analysis, outpacing the broader global outsourcing market by a wide margin. Capital doesn't move at that pace unless investors are already betting on the integrated model.
Frequently asked Questions about CRDMOs, CDMOs, and CROs
What's the difference between a CDMO and a CMO?
A CMO (Contract Manufacturing Organization) is purely an execution partner. It takes a recipe that's already finalised and mass-produces it. A CDMO does that plus the development work. Optimising the chemistry, resolving stability issues, choosing the delivery format (tablet, liquid, injectable), and scaling the process up from scratch.
Who actually supplies the drug material used in a clinical trial?
Not the CRO. CROs manage the patients, the sites, and the data. The physical trial material is formulated, tested, and supplied by a CDMO (or the manufacturing arm of a CRDMO). The CRO's job starts once that material reaches the trial site.
How do compliance requirements differ between the two?
CROs work under GLP (Good Laboratory Practice) for animal studies and GCP (Good Clinical Practice) for human trials, both aimed at protecting data integrity and patient safety. CDMOs operate under cGMP (current Good Manufacturing Practice), which governs product purity, sterility, and batch-to-batch consistency.
How much of pharma is actually outsourced today?
A lot. Roughly three-quarters of late-stage clinical pipelines now rely on CROs for trial execution, and something close to 40% of chemical drug manufacturing is handled by CDMOs and CMOs rather than in-house. Outsourcing isn't the exception anymore for most sponsors; It's the default.
What's the single biggest difference between a CRO and a CDMO?
What they actually deliver. A CRO delivers data — trial results, safety statistics, regulatory dossiers. A CDMO delivers a physical product — a drug substance turned into a stable formulation and packaged into clinical or commercial batches.
When should a biotech hire a CRO instead of a CDMO?
Hire a CRO when the question is whether the drug works — animal studies, clinical trial logistics, patient recruitment, safety monitoring. Hire a CDMO when the question is how to actually make the drug — turning a lab-scale molecule into a stable, manufacturable product and scaling it up.
Can one vendor really do both jobs?
Yes — that's exactly what an integrated CRO CDMO, or CRDMO, is built to do. A growing number of global providers now offer this combined model specifically to remove vendor hand-off risk and keep communication inside one organisation rather than across two.